이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GlycoMimetics 관리

관리 기준 확인 2/4

GlycoMimetics' CEO는 Harout Semerjian, Aug2021 에 임명되었습니다 의 임기는 3.08 년입니다. 총 연간 보상은 $ 2.39M, 26.7% 로 구성됩니다. 26.7% 급여 및 73.3% 보너스(회사 주식 및 옵션 포함). 는 $ 4.41K 가치에 해당하는 회사 주식의 0.039% 직접 소유합니다. 4.41K. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 8 년입니다.

주요 정보

Harout Semerjian

최고 경영자

US$2.4m

총 보상

CEO 급여 비율	26.7%
CEO 임기	3.1yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	8yrs

최근 관리 업데이트

Recent updates

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

May 26

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12

GlycoMimetics EPS beats by $0.04

May 03

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28

New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease

Dec 07

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07

The Investment Case For GlycoMimetics

Nov 17

CEO 보상 분석

Harout Semerjian 의 보수는 GlycoMimetics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$39m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$2m	US$638k	-US$37m
Sep 30 2023	n/a	n/a	-US$38m
Jun 30 2023	n/a	n/a	-US$37m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$1m	US$614k	-US$47m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$64m
Dec 31 2021	US$3m	US$244k	-US$63m

보상 대 시장: Harout 의 총 보상 ($USD 2.39M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Harout 의 보상이 증가했습니다.

CEO

Harout Semerjian (54 yo)

3.1yrs

테뉴어

US$2,389,418

보상

Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...

리더십 팀

이름	위치	테뉴어	보상	소유권
Harout Semerjian	CEO, President & Director	3.1yrs	US$2.39m	0.039% $ 4.2k
Rachel King	Co-Founder & Director	21.7yrs	US$96.00k	0.98% $ 106.1k
Brian Hahn	Senior VP & CFO	12.7yrs	US$1.30m	0.096% $ 10.4k
Edwin Rock	Senior VP & Chief Medical Officer	2yrs	US$1.15m	1.06% $ 113.6k
Stephanie Irish	Vice President of Accounting	5.7yrs	데이터 없음	데이터 없음
Christian Dinneen-Long	General Counsel & Company Secretary	5.4yrs	데이터 없음	데이터 없음
Bruce Johnson	Senior VP & Chief Commercial Officer	2.6yrs	데이터 없음	0.22% $ 23.2k
Chinmaya Rath	Senior VP & Chief Business Officer	1.6yrs	데이터 없음	0.25% $ 26.9k
Shantha Tyavanagimatt	Senior Vice President of Technical Operations	less than a year	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: GLYC 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Harout Semerjian	CEO, President & Director	3.1yrs	US$2.39m	0.039% $ 4.2k
Rachel King	Co-Founder & Director	21.7yrs	US$96.00k	0.98% $ 106.1k
Daniel Junius	Independent Director	8.5yrs	US$118.50k	0.15% $ 16.4k
Timothy Pearson	Independent Chairman of the Board	10.5yrs	US$138.00k	0.038% $ 4.1k
Scott Koenig	Independent Director	7.5yrs	US$100.50k	0.057% $ 6.1k
Scott Jackson	Independent Director	5.8yrs	US$111.00k	0.0081% $ 876.6
Patricia S. Andrews	Independent Director	7.3yrs	US$105.00k	0.091% $ 9.8k
Mark A. Goldberg	Independent Director	10.2yrs	US$111.00k	데이터 없음

8.0yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: GLYC 의 이사회는 경험(평균 재직 기간 7.8 년)으로 간주됩니다.

GlycoMimetics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

Senior VP & Chief Medical Officer recently bought US$90k worth of stock

Chief Medical Officer recently bought US$248k worth of stock

Insider recently bought US$53k worth of stock

Insufficient new directors

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

Recent updates

Glycomimetics Announces to Reduce Its Workforce by Approximately 80%

We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

GlycoMimetics Receives Non-Compliance letter from Nasdaq Regarding Listing Rule 5450(a)(1)

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

New major risk - Financial position

New major risk - Revenue and earnings growth

New minor risk - Profitability

No longer forecast to breakeven

GlycoMimetics, Inc. to Report Q1, 2024 Results on May 09, 2024

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

New minor risk - Profitability

GlycoMimetics Can Become A Game Changer In Blood Cancers

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Price target decreased by 31% to US$5.50

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

GlycoMimetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Senior VP & Chief Medical Officer recently bought US$90k worth of stock

GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

New minor risk - Market cap size

GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

No longer forecast to breakeven

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

Price target decreased by 35% to US$5.50

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Forecast to breakeven in 2025

Chief Medical Officer recently bought US$248k worth of stock

GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Insider recently bought US$53k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

GlycoMimetics has a new Chief Medical Officer

Second quarter 2022 earnings released: US$0.25 loss per share (vs US$0.28 loss in 2Q 2021)

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

GlycoMimetics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$8.50

GlycoMimetics Receives a Notice from Nasdaq Regarding Minimum Bid Price Requirement

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2021)

Insufficient new directors

GlycoMimetics, Inc. to Report Q1, 2022 Results on Apr 28, 2022

GlycoMimetics, Inc., Annual General Meeting, May 18, 2022

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

GlycoMimetics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

GlycoMimetics, Inc. Appoints Bruce Johnson as Senior Vice President and Chief Commercial Officer

Insufficient new directors

Insufficient new directors

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Independent Director recently bought US$82k worth of stock

Price target increased to US$14.50

GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Price target increased to US$14.50

Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

GlycoMimetics, Inc. Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination with Venetoclax and Azacitidine

GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 3000E Value Index

Consensus forecasts updated

GlycoMimetics, Inc. Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

GlycoMimetics EPS beats by $0.04

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Senior VP of Clinical Development & Chief Medical Officer has left the company

Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML